Indaptus Therapeutics, Inc. 8-K

What Happened

• On February 11, 2026, Indaptus Therapeutics announced it entered into warrant repricing agreements that lower the per-share exercise price to $1.75 (the Nasdaq “Minimum Price”) for 913,638 warrants issued in 2024–2025. The company’s board also unilaterally reduced the exercise price to $1.75 for an additional 762,787 warrants and placement agent warrants from the same financings. Original exercise prices on the affected warrants ranged from $8.30 to $47.60.
• As a condition of the negotiated repricings, the holders of the 913,638 “Executing Warrants” agreed to a voting agreement to vote all shares they hold in favor of all proposals at the special stockholder meeting scheduled for February 26, 2026. Other warrant terms remain unchanged.

Key Details

• Date of agreements: February 11, 2026; 8-K filed February 12, 2026.
• Warrants affected: 913,638 repriced by agreement; 762,787 repriced unilaterally by the board — total 1,676,425 warrants.
• New exercise price: $1.75 per share (equal to Nasdaq “Minimum Price” calculation).
• If all affected warrants were exercised at $1.75, gross proceeds would be approximately $2.93 million.

Why It Matters

• Lowering the exercise price makes it more likely warrant holders will exercise, which can increase the company’s outstanding shares and dilute existing shareholders; the total potential share issuance and modest cash inflow (≈$2.9M if fully exercised) could affect capital and ownership structure.
• The negotiated repricing is tied to a voting agreement, meaning those warrant holders committed to support the company’s proposals at the February 26, 2026 special meeting, which could materially influence the meeting’s outcome.
• Investors should review the company’s Definitive Proxy Statement and the filed agreements for details on the proposals being voted on and consider the potential dilution and governance implications before making investment decisions.